BIOS Capital Management, LP

CIK 1813845 · View on SEC EDGAR ↗

Portfolio value
$26.1M
#8,873 of 9,443 by 13F value · top 94.0%
Positions
6
As of
June 30, 2026

Portfolio value QoQ: -8.4% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
5
Effective number of positions
2.5

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 0.0% Est. buys $0 · sells $3,120,457

Median holding: 7.0 quarters Tracked Q4 2024–Q2 2026 · 85.7% still held

New positions
0
Increased
0
Decreased
2
Closed
0
On this page

Performance vs S&P 500

Tracked Q4 2024–Q2 2026
+0.7%
S&P 500 total return (same window)
+28.1%
Excess return
-27.4%

Annualized: +0.5% · S&P 500: +18.0%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

Healthcare
100.0%

Full portfolio 6 positions

Type Streak 8Q trend
IRD Opus Genetics, Inc. - Common Stock $15,138,893 57.96% 3,683,429 $-1,620,709
CGTX Cognition Therapeutics, Inc. - Common Stock $6,324,891 24.22% 5,499,905 $2,144,963
ACTU Actuate Therapeutics, Inc. - Common stock $2,227,458 8.53% 1,455,855 $-1,761,585
RNTX Rein Therapeutics, Inc. - Common Stock $1,272,960 4.87% 1,224,000 $-1,012,928 Down ×1
LTRN Lantern Pharma Inc. - Common Stock $1,039,985 3.98% 249,397 $-144,291 Down ×5
INAB IN8bio, Inc. - Common Stock $114,149 0.44% 80,957 $-5,667

Top movers (QoQ)

Security Action Shares Δ Value Δ
CGTX Price move only +0 +$2.1M
ACTU Price move only +0 -$1.8M
IRD Price move only +0 -$1.6M
RNTX Trimmed -534K -$1.0M
LTRN Trimmed -615K -$144K
INAB Price move only +0 -$6K